View clinical trials related to Secondary Amenorrhea.
Filter by:This study will be a Phase 3, randomized, three-cycle, double-blind, placebo-controlled, parallel group, multiple-dose design. The study design has four phases: Screening Period; Open-Label Estrogen-Priming Period (Run-In Period); Blinded Treatment Period; and Follow-Up. The Open Label Priming Period and Blinded Treatment Period cover a total of three 28-day cycles. Clinical evaluations will be performed at the following time points: Screening Period: • Screening Period (approximately 42 Days) Open-Label Estrogen Priming Period (Run In Period): - Visit 1 Baseline (Cycle 1, Day 1) - Telephone Interview (Cycle 1, Day 28 [- 3 d to ±1d]) Blinded Treatment Period: - Visit 2 Randomization (Cycle 2, Day 12 [±2d]) - Visit 3 Interim (Cycle 3, Day 12 [±2d]) - Visit 4 End of treatment (Cycle 3, Day 24 [±1d]) Follow-Up Period: - Visit 5 Follow-Up (Approximately 10 days after the last treatment) - Telephone Interview (Approximately 2-4 weeks after completion of progestin course) (Only applies to subjects receiving an approved progestin therapy for proliferative endometrium, as determined by biopsy.)
To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea